Highlights BioSenic SA

Equities

BIOS

BE0974280126

Market Closed - Euronext Bruxelles Other stock markets 14:42:31 10/05/2024 BST			5-day change	1st Jan Change
0.0138 ^EUR	+2.22%		+0.73%	-77.45%

04-11	Biosenic: launch of a debt restructuring plan	CF
03-12	Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biosenic: launch of a debt restructuring plan	04-11	CF
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	03-12	CI
BioSenic Unit Wins Canadian Patent for Therapeutic Platform	01-30	MT
BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform	01-30	CI
BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress	01-25	CI
BioSenic Files US Patent for Osteoarthritis Therapy	01-23	MT
BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA	01-23	CI
Biosenic: partnership with Phebra PTY evolves	01-15	CF
BioSenic Signs Binding Term Sheet with Phebra for Oral Formulation Development of cGvHD Treatment	01-15	MT
BioSenic Reaches Agreement on A Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment	01-15	CI
BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD	27/09/23	CI
BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis	19/09/23	CI
BioSenic Secures Patent in China for Arsenic Trioxide Platform	24/08/23	MT
BioSenic S.A. Puts Phase IIb Allob Trial on Hold	19/06/23	CI
BioSenic to Advance Viscosupplement Plans for Knee Osteoarthritis	17/05/23	MT
BioSenic Secures New European Patent for Therapeutic Use of Arsenic Trioxide, Copper Salts	18/04/23	MT
BioSenic S.A. Optimizes Statistical Analysis for its Ongoing ALLOB Phase IIb Study for High-Risk Tibial Fractures, Requiring Fewer Patients and Completes Patient Recruitment	23/02/23	CI
BioSenic Gets EUR1 Million as China Rules Force Pregene to Scrap License Agreement	21/02/23	MT
BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)	08/11/22	CI
BioSenic Provides Phase III Study of cGvHD Currently Anticipated to Start in First Half of 2023	25/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioSenic SA

Equities

BIOS

BE0974280126

Highlights

Filters